Advertisement

Preclinical Pharmacology of Metrifonate: A Promise for Alzheimer Therapy

  • Bernard H. Schmidt
  • Volker C. Hinz
  • Arjan Blokland
  • Franz-Josef van der Staay
  • Richard J. Fanelli
Part of the Advances in Alzheimer Disease Therapy book series (AADT)

Abstract

Among the multiple transmitter deficits which have been described in Alzheimer’s Disease (AD), the degeneration of brain cholinergic cell bodies is the most sensitive, specific and severe, as indicated by the good correlation between the cholinergic pathology and dementia. Therefore, current drug development strategies in AD therapy focus on the enhancement of cholinergic neurotransmission. The most advanced class of compounds in this respect are cholinesterase (ChE) inhibitors which aim to restore the concentration of acetylcholine (ACh) in the synaptic cleft.

Keywords

Cholinesterase Inhibition Subchronic Administration Dimethyl Phosphate Oxime Therapy Dichlorovinyl Dimethyl Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Becker RE and Giacobini E (1988): Mechanisms of Cholinesterase inhibition in senile dementia of the Alzheimer type: clinical, pharmacological, and therapeutic aspects. Drug Dev Res 12:163–195.CrossRefGoogle Scholar
  2. Becker RE, Moriearty P, Surbeck R, Unni L, Varney A and Vicari SK (1994): Second and third generation Cholinesterase inhibitors: clinical aspects. In: Alzheimer Disease: Therapeutic Strategies, Giacobini E and Becker R, eds. Boston: Birkhäuser, pp. 172–178.Google Scholar
  3. Blokland A, Hinz V and Schmidt BH (1995): Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin test: Evaluation of the efficacy/safety profile in rats. Drug Dev Res 36:166–179.CrossRefGoogle Scholar
  4. Hinz V, Grewig S and Schmidt BH (1996a): Metrifonate induces Cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res, in press.Google Scholar
  5. Hinz V, Grewig S and Schmidt BH (1996b): Metrifonate and dichlorvos: Effects of a single oral administration on Cholinesterase activity in rat brain and blood. Neurochem Res, in press.Google Scholar
  6. Holmstedt B, Nordgren I, Sandoz M and Sundwall A (1978): Metrifonate: Summary of toxicological and pharmacological information available. Arch Toxicol 41:3–29.PubMedCrossRefGoogle Scholar
  7. Kronforst MA, Moriearty PL, Ralphs M, Becker RE, Schmidt B, Thompson LT and Disterhoft JF (1995): Facilitation of learning in the aging rabbit after chronic metrifonate treatment. Soc Neurosci Abstr 21:196.Google Scholar
  8. Main AR (1979): Mode of action of anticholinesterases. Pharmacol Ther 6:579–628.CrossRefGoogle Scholar
  9. Mori F, Cuadra G and Giacobini E (1995a): Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 20:1081–1088.PubMedCrossRefGoogle Scholar
  10. Mori F, Lai CC, Fusi F and Giacobini E (1995b): Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuro Report 6:633–636.Google Scholar
  11. Moriearty PL and Becker RE (1992): Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Meth Find Clin Pharmacol 14:615–621.Google Scholar
  12. Reiner E and Plestina R (1979): Regeneration of Cholinesterase activities in humans and rats after inhibition of O,O-dimethyl-2,2-dichlorovinyl phosphate. Toxicol Appl Pharmacol 49:451–454.PubMedCrossRefGoogle Scholar
  13. Soininen HS, Unni L and Shillcutt S (1990): Effect of acute and chronic Cholinesterase inhibition on biogenic amines in rat brain. Neurochem Res 15:1185–1190.PubMedCrossRefGoogle Scholar
  14. van der Staay FJ, Hinz VC and Schmidt BH (1996): Effects of metrifonate on escape and avoidance learning in young and aged rats. Behav Pharmacol 7:56–64.Google Scholar
  15. Villén T, Aden-Abdi Y, Ericsson Ö, Gustafsson LL and Sjöqvist F (1990): Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. J Chromatogr 529:309–317.PubMedCrossRefGoogle Scholar
  16. Weinstock M (1995): The pharmacotherapy of Alzheimer’s disease based on the cholinergic hypothesis: an update. Neurodegeneration 4:349–345.PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1997

Authors and Affiliations

  • Bernard H. Schmidt
    • 1
  • Volker C. Hinz
    • 1
  • Arjan Blokland
    • 1
  • Franz-Josef van der Staay
    • 1
  • Richard J. Fanelli
    • 2
  1. 1.Institute for NeurobiologyTroponwerke GmbH & Co. KGKölnGermany
  2. 2.Institute for Dementia ResearchBayer Corp.West HavenUSA

Personalised recommendations